• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Last 30 days trials
  • A Randomized Phase II Trial of Temozolomide (TMZ) with/without Recentin (AZD2171) in Patients with unresectable Stage IV Malignant Melanoma.

Disease
colorectal cancer
Drug Name
RECENTIN
Generic Name
AZD2171
Sponsor
AstraZeneca
Drug Status
In Development
Phase
II
Start Date
Jan 18, 1971
Study Id
IRUS21710038
Recruiting Status
Open
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013